Details of the Drug

General Information of Drug (ID: DMLW57T)

Drug Name
Teniposide
Synonyms
PTG; Teniposido; Teniposidum; Vehem; Vumon; Demethyl Epipodophyllotoxin Thenylidine Glucoside; VM 26; Teniposido [INN-Spanish]; Teniposidum [INN-Latin]; VM-26; Vee M-26; Veham-Sandoz; Vumon (TN); Teniposide (USAN/INN); Teniposide [USAN:BAN:INN]; VM-26 (TN); Vumon, VM-26, Vehem, NSC 122819, Teniposide; Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside); 4'-Demethyl-epipodophyllotoxin-beta-D-thenylidene-glucoside; 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-2-thenylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin thenylidene glucoside; 4'-Demethylepipodophyllotoxin-beta-D-thenylidine glucoside; 4'-Dimethyl-9-(4,6-O-2-thenyid)-epipodophyllotoxin; 4-Demethylepipodophyllotoxin-.beta.-D-thenylideneglucoside
Indication
Disease Entry ICD 11 Status REF
Acute lymphoblastic leukaemia 2A85 Approved [1]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 2 Molecular Weight (mw) 656.7
Logarithm of the Partition Coefficient (xlogp) 1.2
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 14
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Clearance
The drug present in the plasma can be removed from the body at the rate of 0.19 mL/min/kg [3]
Elimination
9% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 5 hours [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 10.65988 micromolar/kg/day [4]
Unbound Fraction
The unbound fraction of drug in plasma is 0.0044% [3]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.41 L/kg [3]
Water Solubility
The ability of drug to dissolve in water is measured as 0.025 mg/mL [2]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Cytogenetic abnormality Not Available G6PD OT300SMK [5]
Cytogenetic abnormality Not Available TOP2A OT6LPS08 [5]
Cytogenetic investigations Not Available TOP1 OT51O0CF [5]
Chemical Identifiers
Formula
C32H32O13S
IUPAC Name
(5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one
Canonical SMILES
COC1=CC(=CC(=C1O)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@@H](C4=CC5=C(C=C24)OCO5)O[C@H]6[C@@H]([C@H]([C@H]7[C@H](O6)CO[C@H](O7)C8=CC=CS8)O)O
InChI
InChI=1S/C32H32O13S/c1-37-19-6-13(7-20(38-2)25(19)33)23-14-8-17-18(42-12-41-17)9-15(14)28(16-10-39-30(36)24(16)23)44-32-27(35)26(34)29-21(43-32)11-40-31(45-29)22-4-3-5-46-22/h3-9,16,21,23-24,26-29,31-35H,10-12H2,1-2H3/t16-,21+,23+,24-,26+,27+,28+,29+,31+,32-/m0/s1
InChIKey
NRUKOCRGYNPUPR-QBPJDGROSA-N
Cross-matching ID
PubChem CID
452548
CAS Number
29767-20-2
DrugBank ID
DB00444
TTD ID
D01DBQ
VARIDT ID
DR00021
INTEDE ID
DR1550

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA topoisomerase II (TOP2) TT0IHXV TOP2A_HUMAN ; TOP2B_HUMAN Modulator [6]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 3 (ABCC3) DTQ3ZHF MRP3_HUMAN Substrate [7]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [8]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [9]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [10]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [11]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Cholesteryl ester transfer protein (CETP) OTAGPPOE CETP_HUMAN Gene/Protein Processing [12]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Gene/Protein Processing [12]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Biotransformations [11]
Cytochrome P450 3A5 (CYP3A5) OTSXFBXB CP3A5_HUMAN Biotransformations [11]
DNA topoisomerase 1 (TOP1) OT51O0CF TOP1_HUMAN Drug Response [5]
DNA topoisomerase 2-alpha (TOP2A) OT6LPS08 TOP2A_HUMAN Drug Response [5]
Fibroblast growth factor 2 (FGF2) OT7YUJ9F FGF2_HUMAN Drug Response [13]
Glucose-6-phosphate 1-dehydrogenase (G6PD) OT300SMK G6PD_HUMAN Drug Response [5]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Gene/Protein Processing [14]
Nuclear receptor-interacting protein 1 (NRIP1) OTIZOJQV NRIP1_HUMAN Gene/Protein Processing [12]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Teniposide
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Vincristine DMINOX3 Minor Decreased metabolism of Teniposide caused by Vincristine mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [15]
Coadministration of a Drug Treating the Disease Different from Teniposide (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Arn-509 DMT81LZ Moderate Accelerated clearance of Teniposide due to the transporter induction by Arn-509. Acute myeloid leukaemia [2A60] [16]
Dronedarone DMA8FS5 Moderate Decreased metabolism of Teniposide caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [17]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Teniposide and Roflumilast. Asthma [CA23] [16]
Ofloxacin DM0VQN3 Minor Decreased absorption of Teniposide due to intestinal mucosa variation caused by Ofloxacin. Bacterial infection [1A00-1C4Z] [18]
Ciprofloxacin XR DM2NLS9 Minor Decreased absorption of Teniposide due to intestinal mucosa variation caused by Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [18]
Trovafloxacin DM6AN32 Minor Decreased absorption of Teniposide due to intestinal mucosa variation caused by Trovafloxacin. Bacterial infection [1A00-1C4Z] [18]
Sparfloxacin DMB4HCT Minor Decreased absorption of Teniposide due to intestinal mucosa variation caused by Sparfloxacin. Bacterial infection [1A00-1C4Z] [18]
Gemifloxacin DMHT34O Minor Decreased absorption of Teniposide due to intestinal mucosa variation caused by Gemifloxacin. Bacterial infection [1A00-1C4Z] [18]
Norfloxacin DMIZ6W2 Minor Decreased absorption of Teniposide due to intestinal mucosa variation caused by Norfloxacin. Bacterial infection [1A00-1C4Z] [18]
ABT-492 DMJFD2I Minor Decreased absorption of Teniposide due to intestinal mucosa variation caused by ABT-492. Bacterial infection [1A00-1C4Z] [18]
Levofloxacin DMS60RB Minor Decreased absorption of Teniposide due to intestinal mucosa variation caused by Levofloxacin. Bacterial infection [1A00-1C4Z] [18]
Lomefloxacin DMVRH9C Minor Decreased absorption of Teniposide due to intestinal mucosa variation caused by Lomefloxacin. Bacterial infection [1A00-1C4Z] [18]
Telithromycin DMZ4P3A Moderate Decreased metabolism of Teniposide caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [19]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Teniposide caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [20]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Teniposide caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [21]
Tucatinib DMBESUA Moderate Decreased metabolism of Teniposide caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [22]
Mifepristone DMGZQEF Moderate Decreased metabolism of Teniposide caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [23]
MK-8228 DMOB58Q Moderate Decreased metabolism of Teniposide caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [24]
Aprepitant DM053KT Moderate Decreased metabolism of Teniposide caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [25]
Primidone DM0WX6I Moderate Increased metabolism of Teniposide caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [26]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Teniposide caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [26]
Cenobamate DM8KLU9 Moderate Increased metabolism of Teniposide caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [27]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Teniposide caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [26]
Phenobarbital DMXZOCG Moderate Increased metabolism of Teniposide caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [26]
Carbamazepine DMZOLBI Moderate Increased metabolism of Teniposide caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [26]
Tazemetostat DMWP1BH Moderate Increased metabolism of Teniposide caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [28]
Boceprevir DMBSHMF Moderate Decreased metabolism of Teniposide caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [29]
Telaprevir DMMRV29 Moderate Decreased metabolism of Teniposide caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [30]
Rifapentine DMCHV4I Moderate Increased metabolism of Teniposide caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [31]
Brentuximab vedotin DMWLC57 Moderate Increased risk of peripheral neuropathy by the combination of Teniposide and Brentuximab vedotin. Hodgkin lymphoma [2B30] [32]
Delavirdine DM3NF5G Minor Decreased metabolism of Teniposide caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [33]
Efavirenz DMC0GSJ Moderate Increased metabolism of Teniposide caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [34]
Etravirine DMGV8QU Moderate Increased metabolism of Teniposide caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [35]
Zalcitabine DMH7MUV Moderate Increased risk of peripheral neuropathy by the combination of Teniposide and Zalcitabine. Human immunodeficiency virus disease [1C60-1C62] [36]
Darunavir DMN3GCH Moderate Decreased metabolism of Teniposide caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [37]
Teriflunomide DMQ2FKJ Major Additive immunosuppressive effects by the combination of Teniposide and Teriflunomide. Hyper-lipoproteinaemia [5C80] [38]
Conivaptan DM1V329 Moderate Decreased metabolism of Teniposide caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [39]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Teniposide caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [40]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Teniposide and Denosumab. Low bone mass disorder [FB83] [41]
Brigatinib DM7W94S Moderate Increased metabolism of Teniposide caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [42]
Ceritinib DMB920Z Moderate Decreased metabolism of Teniposide caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [16]
PF-06463922 DMKM7EW Moderate Increased metabolism of Teniposide caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [43]
Selpercatinib DMZR15V Moderate Decreased metabolism of Teniposide caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [44]
IPI-145 DMWA24P Moderate Decreased metabolism of Teniposide caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [45]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Teniposide caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [16]
Exjade DMHPRWG Moderate Decreased metabolism of Teniposide caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [46]
Thalidomide DM70BU5 Major Additive thrombogenic effects by the combination of Teniposide and Thalidomide. Multiple myeloma [2A83] [47]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Teniposide and Tecfidera. Multiple sclerosis [8A40] [48]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Teniposide and Siponimod. Multiple sclerosis [8A40] [23]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Teniposide and Fingolimod. Multiple sclerosis [8A40] [49]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Teniposide and Ocrelizumab. Multiple sclerosis [8A40] [50]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Teniposide and Ozanimod. Multiple sclerosis [8A40] [16]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Teniposide caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [16]
Nilotinib DM7HXWT Moderate Decreased clearance of Teniposide due to the transporter inhibition by Nilotinib. Myeloproliferative neoplasm [2A20] [51]
Dasatinib DMJV2EK Moderate Decreased metabolism of Teniposide caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [52]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Teniposide and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [53]
Modafinil DMYILBE Minor Increased metabolism of Teniposide caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [54]
Entrectinib DMMPTLH Moderate Decreased metabolism of Teniposide caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [16]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Teniposide caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [55]
Abametapir DM2RX0I Moderate Decreased metabolism of Teniposide caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [56]
Lefamulin DME6G97 Moderate Decreased metabolism of Teniposide caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [57]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Teniposide caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [58]
Enzalutamide DMGL19D Moderate Increased metabolism of Teniposide caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [59]
Bosentan DMIOGBU Moderate Increased metabolism of Teniposide caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [60]
Gatifloxacin DMSL679 Minor Decreased absorption of Teniposide due to intestinal mucosa variation caused by Gatifloxacin. Respiratory infection [CA07-CA4Z] [18]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Teniposide and Canakinumab. Rheumatoid arthritis [FA20] [61]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Teniposide and Rilonacept. Rheumatoid arthritis [FA20] [61]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Teniposide and Golimumab. Rheumatoid arthritis [FA20] [62]
Leflunomide DMR8ONJ Major Additive immunosuppressive effects by the combination of Teniposide and Leflunomide. Rheumatoid arthritis [FA20] [38]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Teniposide when combined with Anthrax vaccine. Sepsis [1G40-1G41] [63]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Teniposide caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [64]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Teniposide caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [16]
Larotrectinib DM26CQR Moderate Decreased metabolism of Teniposide caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [23]
Armodafinil DMGB035 Minor Increased metabolism of Teniposide caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [54]
LEE011 DMMX75K Moderate Decreased metabolism of Teniposide caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [65]
Fostamatinib DM6AUHV Moderate Decreased clearance of Teniposide due to the transporter inhibition by Fostamatinib. Thrombocytopenia [3B64] [66]
Azathioprine DMMZSXQ Moderate Additive immunosuppressive effects by the combination of Teniposide and Azathioprine. Transplant rejection [NE84] [23]
Cinoxacin DM4EWNS Minor Decreased absorption of Teniposide due to intestinal mucosa variation caused by Cinoxacin. Urinary tract infection [GC08] [18]
Nalidixic acid DMRM0JV Minor Decreased absorption of Teniposide due to intestinal mucosa variation caused by Nalidixic acid. Urinary tract infection [GC08] [18]
Enoxacin DMYTE6L Minor Decreased absorption of Teniposide due to intestinal mucosa variation caused by Enoxacin. Urinary tract infection [GC08] [18]
Ganciclovir DM1MBYQ Moderate Additive myelosuppressive effects by the combination of Teniposide and Ganciclovir. Virus infection [1A24-1D9Z] [23]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Teniposide and Valganciclovir. Virus infection [1A24-1D9Z] [23]
⏷ Show the Full List of 82 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6843).
2 BDDCS applied to over 900 drugs
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem. 2001 Dec 7;276(49):46400-7.
8 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
9 Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes. Int J Clin Pharmacol Ther. 2001 Dec;39(12):517-28.
10 Drug Interactions Flockhart Table
11 O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol. 1994 Feb;45(2):352-8.
12 Regulation of Hepatic Cholesteryl Ester Transfer Protein Expression and Reverse Cholesterol Transport by Inhibition of DNA Topoisomerase II. J Biol Chem. 2015 Jun 5;290(23):14418-29. doi: 10.1074/jbc.M115.643015. Epub 2015 Apr 25.
13 Adenovirus-mediated transfer of siRNA against basic fibroblast growth factor mRNA enhances the sensitivity of glioblastoma cells to chemotherapy. Med Oncol. 2011 Mar;28(1):24-30. doi: 10.1007/s12032-010-9445-z. Epub 2010 Feb 24.
14 Suppression of c-myc expression and c-Myc function in response to sustained DNA damage in MCF-7 breast tumor cells. Biochem Pharmacol. 2001 Sep 1;62(5):593-602. doi: 10.1016/s0006-2952(01)00699-2.
15 Product Information. Oncovin (vincristine). Lilly, Eli and Company, Indianapolis, IN.
16 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
17 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
18 Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
19 Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
20 Product Information. Sonata (zaleplon) Wyeth-Ayerst Laboratories, Philadelphia, PA.
21 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
22 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
23 Cerner Multum, Inc. "Australian Product Information.".
24 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
25 Charasson V, Haaz MC, Robert J "Determination of Drug Interactions Occurring with the Metabolic Pathways of Irinotecan." Drug Metab Dispos 30 (2002): 731-733. [PMID: 12019202]
26 Baker DK, Relling MV, Pui CH, Christensen ML, Evans WE, Rodman JH "Increased teniposide clearance with concomitant anticonvulsant therapy." J Clin Oncol 10 (1992): 311-5. [PMID: 1732431]
27 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
28 Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41. [PMID: 10721388]
29 Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
30 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
31 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
32 Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201. [PMID: 7756727]
33 Cheng CL, Smith DE, Carver PL, Cox SR, Watkins PB, Blake DS, Kauffman CA, Meyer KM, Amidon GL, Stetson PL "Steady-state pharmacokinetics of delavirdine in HIV-positive patients: Effect on erythromycin breath test." Clin Pharmacol Ther 61 (1997): 531-43. [PMID: 9164415]
34 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
35 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
36 Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
37 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
38 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
39 Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
40 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
41 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
42 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
43 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
44 Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
45 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
46 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
47 Figg WD, Arlen P, Gulley J, et al. "A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer." Semin Oncol 28(4 Suppl 15) (2001): 62-6. [PMID: 11685731]
48 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
49 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
50 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
51 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
52 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
53 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
54 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
55 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
56 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
57 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
58 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
59 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
60 Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
61 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
62 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
63 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
64 Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8. [PMID: 8162660]
65 DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
66 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.